directly to content (skip navigation)
Everything you always wanted to know (but were afraid to ask): Abbreviations, acronyms, jargon, and symbols seen – not only – in the BEBA-Forum.
Non-English terms are typeset in italics.
| Term | Meaning |
|---|---|
| a | |
| A | Test treatment in a 2×2×2 crossover design (in comparative BA commonly denoted T) |
| AAA | Amino acid analysis |
| AAAS | American Association for the Advancement of Science |
| AAM | Association for Accessible Medicines (US; until 2017 GPhA) |
| AAPS | American Association of Pharmaceutical Scientists |
| Ab | Antibody |
| ABCM | AUC below \(\textsf{C}_\textsf{min,ss}\) |
| ABE | (Conventional, unscaled) Average Bioequivalence |
| ABEL | Average BE with Expanding Limits (EEA, HC, EEU, WHO, …) |
| AC | Anticoagulant |
| ACC | Accuracy |
| ACCSQ | Consultative Committee for Standards and Quality (ASEAN states) |
| ACE | Angiotensin-converting enzyme |
| ACEI | Angiotensin Converting Enzyme Inhibitor |
| ACK | Acknowledge(d) |
| ACN | Acetonitrile |
| ACPSCP | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (FDA) |
| ACRO | Association of Clinical Research Organizations |
| ACTA | Anti-Counterfeiting Trade Agreement |
| ADaM | Analysis Data Model (of the CDISC) |
| ADC | Antibody Drug Conjugate |
| ADCC | Antibody-dependent Cell-mediated Cytotoxicity |
| ad lib | ad libitum (as desired, freely) |
| ADME | Absorption, Distribution, Metabolism, Excretion |
| ADR | Adverse Drug Reaction |
| AE |
|
| AED | Anti-epileptic Drug |
| Aet | Cumulative amount excreted to the last sampling interval |
| AEMPS | Agencia Española de Medicamentos y Productos Sanitarios (Agency of Medicines and Medical Devices, competent authority of Spain) |
| AFAIK | As far as I know |
| AFSSAPS | Agence française de sécurité sanitaire des produits de santé (French Agency for the Safety of Health Products; since May 2012 ANSM) |
| Ag | Antigen |
| AGAH | Arbeitsgemeinschaft für Angewandte Humanpharmakologie (Association for Applied Human Pharmacology, Germany) |
| AGES | Österreichische Agentur für Gesundheit und Ernährungssicherheit (Austrian Agency for Health and Food Safety) |
| AI | Artificial (Un‽)Intelligence |
| AIC | Akaike Information Criterion |
| aka | also known as |
| ALCOA | Attributable, legible, contemporaneous, original and accurate |
| ALT | Alanine aminotransferase |
| AMA | American Medical Association |
| AMIP | Moroccan Association for the Pharmaceutical Industry |
| AMS | Accelerator Mass Spectrometry |
| ANAFAM | Asociación Nacional de Fabricantes de Medicamentos (National Association of Medicines Manufacturers, Mexico) |
| ANAMED | Agencia Nacional de Medicamentos (National Medicines Agency, Chile) |
| ANCOVA | Analysis of Covariance |
| ANDA | Abbreviated New Drug Application (FDA term) |
| ANMAT | Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (National Administration for Medicines, Food and Medical Technology, Argentina) |
| ANOVA | Analysis of Variance (aka AOV) |
| ANPP | Agence Nationale des Produits Pharmaceutiques (National Agency of Pharmaceutical Products, Algeria) |
| ANSI | American National Standards Institute |
| ANSM | Agence nationale de sécurité du médicament et des produits de santé (National Drug and Health Products Safety Agency, competent authority of France; until April 2012 AFSSAPS) |
| ANVISA | Agência Nacional de Vigilância Sanitária (National Agency for Sanitary Monitoring, Brazil) |
| AOAC | Association of Official Analytical Chemists (US) |
| AOV | Analysis of Variance (aka ANOVA) |
| a.p. | ante prandium (before a meal) |
| AP, A&P | Accuracy and Precision (BMV) |
| APCI | Atmospheric Pressure Chemical Ionization (MS) |
| APEC | Asia-Pacific Economic Cooperation |
| APhA |
|
| API |
|
| APV | Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik (Association for Pharmaceutical Technology, Germany) |
| AR |
|
| ARE | Amount Remaining to be Excreted |
| ARGOM | Australian Regulatory Guideline for OTC Medicines |
| ARGPM | Australian Regulatory Guidelines for Prescription Medicines |
| ARO | Academic Research Organization |
| ASA | American Statistical Association |
| ASAP | As soon as possible (for your health: As slow as possible) |
| ASCII | American Standard Code for Information Interchange |
| ASEAN | Association of Southeast Asian Nations (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam) |
| ASMS | American Society for Mass Spectrometry |
| ASN | Average Total Sample Size (in a TSD) |
| AST | Aspartate aminotransferase |
| AT | Ambient temperature |
| ATC | Anatomical Therapeutic Chemical (Classification System by the WHO) |
| ATMP | Advanced-Therapy Medicinal Product |
| ATP | Adenosine triphosphate |
| AUC |
|
| AUCall | AUClast plus the area of a triangle given by \(\textsf{t}_\textsf{last}|\textsf{C}_\textsf{last}\) and \(\textsf{t}_{\textsf{last}+1}|\textsf{C}=0\) (a questionable invention by Certara; should be avoided) |
| \(\textsf{AUC}_\textsf{apical}\) | Average of AUCs within POT-25 |
| \(\textsf{AUC}_\textsf{extrap}\) | Extrapolated part of the AUC; commonly in percent \(100(\textsf{AUC}_{0-\infty}-\textsf{AUC}_{0-\textsf{t}})/\textsf{AUC}_{0-\infty}\) |
| \(\textsf{AUC}_\textsf{t}\) | AUC from t = 0 to the time point of the last measured concentration (also \(\textsf{AUC}_\textsf{0–t}\), \(\textsf{AUC}_{\textsf{t}_\textsf{last}}\), \(\textsf{AUC}_{\textsf{t}_\textsf{z}}\), AUClast) |
| \(\textsf{AUC}_\textsf{τ}\) | AUC within one dosing interval \(\textsf{τ}\) in steady state (also \(\textsf{AUC}_{0-\textsf{τ}}\)) |
| \(\textsf{AUC}_\infty\) | AUC from t = 0 to infinite time (also \(\textsf{AUC}_{0-\infty}\), AUCinf) |
| \(\textsf{AUEC}\) | Area Under the Effect Curve |
| \(\textsf{AUMC}\) | Area Under the first Moment of the Curve \(=\int \textsf{t}\cdot \textsf{C}(\textsf{t})d \textsf{t}\) |
| Term | Meaning |
|---|---|
| B | Reference treatment in a 2×2×2 crossover design (in comparative BA commonly denoted R) |
| BA |
|
| BABP | Network On Bioavailability And Biopharmaceutics (EUFEPS) |
| BAN | British Adopted Name |
| BAPI | Bangladesh Association of Pharmaceutical Industries |
| BASG | Bundesamt für Sicherheit im Gesundheitswesen (Federal Office for Safety in Health Care, Austria) |
| BBB | Blood–brain barrier |
| BBBB | (Balaton, Bosporus, Bled, Baltic) Conference Series |
| BCS | Biopharmaceutics Classification System |
| BDDCS | Biopharmaceutics Drug Disposition Classification System |
| BE | Bioequivalence (NB, there are no ‘BE studies’ – BE is the desired result of a comparative BA study) |
| bear | |
| BE NOC | Bioequivalence No Objection Certificate (CDSCO term) |
| BEWGG | Bioequivalence Working Group for Generics (of the IPRP) |
| BfArM | Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices, competent authority of Germany; until 1994 BGA) |
| BGA | Bundesgesundheitsamt (Federal Health Office, Germany; rebranded in 1994 to BfArM) |
| BIBD | Balanced Incomplete Block Design |
| BIC | Bayesian Information Criterion (aka SBC) |
| BID | bis in die (twice a day) |
| BLA | Biologics License Application (FDA term) |
| BLQ | Below the LOQ (not quantifiable) |
| BLUE | Best Linear Unbiased Estimator |
| BMI | Body Mass Index |
| BMV | Bioanalytical Method Validation |
| BMWP | Biosimilar Medicinal Products Working Party (of the EMA) |
| BP | Blood pressure |
| BPFK | Biro Pengawalan Farmaseutikal Kebangsaan (National Pharmaceutical Control Bureau, Malaysia) |
| BQL | Below Quantification Limit |
| B-R | Benefit-Risk |
| BS | Blood Sugar |
| BSA |
|
| BSCV | Between-subjects CV (also CVB, CVinter) |
| BS | Blood Sugar |
| BSI | Body Shape Index |
| BSWP | Biostatistics Working Party (of the CHMP); merged 2022 with other working parties in the MWP |
| BTIF | Bioequivalence Trial Information Form (WHO) |
| BTW | By the way |
| BW |
|
| BWG | Biosimilars Working Group (of the IPRP) |
| BWP | Biologics Working Party (of the EMA) |
| BZD | Benzodiazepine |
| Term | Meaning |
|---|---|
| \(\textsf{C}\) | (Measured, observed) concentration |
| \(\widehat{\textsf{C}}\) | Estimated concentration |
| \(\widehat{\textsf{C}}_\textsf{0}\) | Intercept in the log-linear estimation of \(\widehat{\lambda}_\textsf{z}\) |
| ca. | circa (approximately) |
| CA | Competent Authority |
| Caco-2 | Human colon adenocarcinoma cell line |
| cAMP | Cyclic adenosine monophosphate |
| CAP | Centrally Authorised Product (EMA) |
| CAPA | Corrective and Preventive Action |
| \(\textsf{C}_\textsf{apical}\) | Average of concentrations within POT-25 |
| CAP | Centrally Authorised Product (in the EEA) |
| CAS |
|
| CAT | Committee for Advanced Therapies (of the EMA) |
| \(\textsf{C}_\textsf{av,ss}\) | Average concentration in steady state \(=\textsf{AUC}_{0-\textsf{τ}}/\textsf{τ}\) |
| CBER | Center for Biologics Evaluation and Research (of the FDA) |
| CC |
|
| CD | Circular Dichroism |
| CDD | Critical Dose Drug |
| CDE | Center For Drug Evaluation (Taiwan) |
| CDER | Center for Drug Evaluation and Research (of the FDA) |
| CDF | Cumulative Distribution Function |
| CDISC | Clinical Data Interoperability Standards Consortium |
| CDMO | Contract, Development and Manufacturing Organization |
| CDS | Chromatography Data System |
| CDSCO | Central Drugs Standard Control Organization (India) |
| CE |
|
| CECMED | Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (Center for State Control of Medicines, Equipment, and Medical Devices, Cuba) |
| CEP | Clinical Endpoint |
| CET | Central European Time (UTC+1) |
| CEST | Central European Summer Time (UTC+2) |
| CFDA | China Food & Drug Administration (formerly SFDA) |
| CEX | Cation Exchange |
| CFR | Code of Federal Regulations (US) |
| cGMP |
|
| CGPA | Canadian Generic Pharmaceutical Association |
| CHMP | Committee for Medicinal Products for Human Use (of the EMA; until 2004 CPMP) |
| CHO | Carbohydrate |
| CI |
|
| CILFA | Cámara Industrial de Laboratorios Farmacéuticos Argentinos (Argentinian Generic and Biosimilar Pharmaceutical Manufacturers Association) |
| CIOMS | Council for International Organizations of Medical Sciences |
| CIP | Cahn–Ingold–Prelog priority rules |
| CL |
|
| \(\textsf{C}_\textsf{last}\) | Last measured concentration of the profile |
| \(\widehat{\textsf{C}}_\textsf{last}\) | Estimated last concentration of the profile |
| CL/ƒ | Apparent Clearance after extravascular administration |
| CLIA | Clinical Laboratory Improvement Amendments |
| \(\textsf{C}_\textsf{max},\,\textsf{C}_\textsf{max,ss}\) | Maximum concentration (single dose, steady state); observed in NCA, estimated by PK modeling |
| CMC | Chemistry, Manufacturing, and Controls |
| CMDh | Co-ordination group for Mutual recognition and Decentralised procedures – human (of the EEA; until 2005 MRFG) |
| \(\textsf{C}_\textsf{min,ss}\) | Minimum concentration in steady state (also \(\textsf{C}_\textsf{trough}\)) |
| CMS | Concerned Member State (in European MRP) |
| CMV | Critical Model Variable |
| CNS | Central Nervous System |
| CO | Carryover |
| CoA | Certificate of Analysis |
| CoC | Code of Conduct |
| COFEPRIS | Comisión Federal para la Protección contra Riesgos Sanitarios (Federal Commission for Protection against Health Risks, Mexico) |
| COI | Conflict of interest |
| COMP | Committee for Orphan Medicinal Products (of the EMA) |
| CONSORT | Consolidated Standards of Reporting Trials |
| COPD | Chronic Obstructive Pulmonary Disease |
| COST | European Cooperation in Science and Technology |
| COSTART | Coding Symbols for a Thesaurus of Adverse Reaction Terms (FDA; replaced by the MedDRA) |
| COTS | Commercial off-the-shelf |
| CP |
|
| CPD | Citrate Phosphate Dextrose (AC) |
| CPDA | Citrate Phosphate Dextrose Adenine (AC) |
| CPMP | Committee for Proprietary Medicinal Products (of the EMA; since 2004 CHMP) |
| CPPS | Center for Pharmaceutical Products Safety, Uzbekistan |
| CQA | Critical Quality Attribute |
| CR | Controlled Release MR product (also LA, SR, XR) |
| CRA | Clinical Research Associate |
| CRAN | Comprehensive |
| CRF | Case Report Form |
| CRM | Continual Reassessment Method |
| CRO | Contract Research Organization |
| CRP | Conditional Rejection Probability |
| CSV | Character Separated Variables (originally: Comma Separated Variables) |
| CSF | Cerebrospinal Fluid |
| CSP | Clinical Study Protocol |
| CSR | Clinical Study Report |
| CSS | Cascading Style Sheet |
| CT |
|
| \(\textsf{C}_\textsf{τ}\) | Concentration at intended dosing interval \(\textsf{τ}\) after a single dose |
| \(\textsf{C}_{\textsf{τ},\textsf{ss}}\) | Concentration at the end of the dosing interval \(\textsf{τ}\) in steady state |
| CTA | Clinical Trial Application |
| CTC | Common Toxicity Criteria |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTD | |
| CTM | Clinical Trial Manager |
| CTR(I) | Clinical Trial Registry (India) |
| \(\textsf{C}_\textsf{trough}\) | |
| CV |
|
| CVG | Calibration and Validation Group |
| CVinter | Between-subjects CV estimated in a crossover design (aka CVB, BSCV) |
| CVintra | Within-subjects CV estimated in a crossover design (aka CVW, ISCV) |
| CVtotal | CV estimated in a parallel design (aka CVpooled) |
| CVwR | Within-subjects CV of the Reference product estimated in a replicate design |
| CVwT | Within-subjects CV of the Test product estimated in a fully replicated design |
| CYP | Cytochrome Pigment |
| Term | Meaning |
|---|---|
| d |
|
| d | dextro enantiomer, according to IUPAC (+) |
| D | Dose |
| DABERS | Data Anomalies in BioEquivalence R Shiny (a tool of the FDA) |
| DAD | Diode Array Detector (LC) |
| DAR | Drug-antibody ratio |
| DB | Database |
| DBE | Division of Bioequivalence (FDA/OGD) |
| DBP | Diastolic blood pressure |
| DBS | Dried Blood Spot |
| DCD | Drug Control Division (competent authority of Thailand) |
| DCGI | Drug Controller General of India |
| DCL | Data Control Language (of SQL) |
| DCP | Decentralised Procedure (in the EEA) |
| DCR | Division of Clinical Review (FDA/OGD) |
| DCS | Developability Classification System |
| DDD | Defined daily dose (WHO term) |
| DDI | Drug-Drug Interaction |
| DDL | Data Definition Language (of SQL) |
| DDT | Drug Development Tool |
| DE | Dissolution Efficiency |
| DES | Drug-eluting stent |
| DESI | Drug efficacy study implementation |
| df | Degree(s) of freedom (also \(\nu\)) |
| DGDA | Directorate General of Drug Administration (competent authority of Bangladesh) |
| DHMA | Danish Health and Medicines Authority (in 2012 merged from DKMA and the National Board of Health) |
| DIA | Drug Information Association |
| DII | Director of Investigating Institute (GLP) |
| DINAVISA | Dirección National de Vigilancia Sanitaria (National Health Surveillance Directorate, Paraguay) |
| DKMA | Danish Medicines Agency (since 2012 DHMA) |
| DL |
|
| DLP | Data Lock Point |
| DLS | Dynamic Light Scattering |
| DLT | Dose Limiting Toxicity |
| DMC | Data Monitoring Committee |
| DM | Mahalanobis Distance (also MD) |
| DMF | Drug Master File |
| DML | Data Manipulation Language (of SQL) |
| DMS | Document Management System |
| DMPK | Drug Metabolism and Pharmacokinetics |
| DNFTT | Do not feed the Troll |
| DO(R) | Dropout (rate) |
| DOI | Digital Object Identifier |
| DP | Drug Product |
| DQ | Design Qualification |
| DQC | Dilution Quality Control |
| DQL | Data Query Language (of SQL) |
| DR | Delayed Release |
| DRF | Data Resolution Form |
| DS | Drug Substance |
| DSC | Differential Scanning Calorimetry |
| DSMB | Data Safety Monitoring Board |
| DST | Daylight saving time |
| D-U-N-S | Data Universal Numbering System |
| DV | Dependent variable |
| Term | Meaning |
|---|---|
| E | Effect |
| EA | Ethyl acetate (aka EtOAc) |
| EAC | East African Community (Democratic Republic of the Congo, Federal Republic of Somalia, Republics of Burundi, Kenya, Rwanda, South Sudan, Uganda, and Tanzania) |
| EACPT | European Association for Clinical Pharmacology and Therapeutics |
| EAEU, EEU | Eurasian Economic Union (Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia) |
| EBE | European Biopharmaceutical Enterprises |
| EBF | European Bioanalysis Forum |
| EBM | Evidence-based medicine |
| EC |
|
| EC50 | Median Effective Concentration |
| ECD | |
| ECG | Electrocardiography, Electrocardiogram |
| ECHI | European Core Health Indicators of the EC |
| eCRF | Electronic Case Report Form |
| eCTD | Electronic Common Technical Document |
| ED | Erectile dysfunction |
| ED50 | Median Effective Dose |
| EDA |
|
| EDC | Electronic Data Capturing |
| EDCS | Electronic Data Capture System |
| EDF | Empirical Distribution Function |
| EDL | Estimate of the Detection Limit (EPA term) |
| EDMS | Electronic Data Management System |
| EDQM | European Directorate for the Quality of Medicines & HealthCare |
| EDTA | Ethylenediaminetetraacetic acid (AC) |
| EEA | European Economic Area (EU + Iceland, Liechtenstein, Norway) |
| EEC | Commission of the EEU |
| EEG | Electroencephalography, Electroencephalogram |
| EFPIA | European Federation of Pharmaceutical Industries and Associations |
| e.g. | exempli gratia (for example) |
| EGA | European Generic Medicines Association (since 2016 MfE) |
| EI | Electron Impact Ionization (MS) |
| EIR | Establishment Inspection Report (FDA) |
| ELISA | Enzyme Linked Immunosorbent Assay |
| ELS | Evaporative Light Scattering |
| EM | |
| EMA | European Medicines Agency (until 2005 EMEA) |
| Emax | Maximum Effect |
| EMEA | European Agency for the Evaluation of Medicinal Products (rebranded in 2005 to EMA) |
| EMG | Exponentially Modified Gaussian |
| EMIT | Enzyme Multiplied Immunoassay Technique |
| EML | Essential Medicines List (WHO) |
| EOB | Electronic Orange Book (FDA) |
| EOD |
|
| EORI | Economic Operators Registration and Identification number (EU) |
| EPA | Environmental Protection Agency (US) |
| EPAR | European Public Assessment Report |
| EPO | Erythropoietin |
| ER | Extended Release (MR product) |
| ES | Eligible subject |
| ESI | Electrospray Ionization (MS) |
| ESV | End of Study Visit |
| et al. | et alii (and others) |
| ETASU | Elements to Assure Safe Use (FDA term) |
| EtOAc | Ethyl acetate (aka EA) |
| EtOH | Ethanol |
| EU | European Union (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden; 01/2020 |
| EUCROF | European CRO Federation |
| EudraCT | EU Drug Regulating Authorities Clinical Trials |
| EudraLex | Collection of rules and regulations governing medicinal products in the EU |
| EudraNet | EU Drug Regulating Authorities Network |
| EudraGMDP | EEA Good Manufacturing / Distribution Practice Database |
| EudraPharm | EU Drug Regulating Authorities Pharmaceutical Database |
| EUFEPS | European Federation for Pharmaceutical Sciences |
| EULA | End-user license agreement (aka software license agreement) |
| EUnetHTA | European Network for Health Technology Assessment |
| EV | Extravascular (also ev) |
| EWG | Expert Working Group (of the ICH) |
| EWP | Efficacy Working Party (of the EMA) |
| EX | Excitation wavelength (FL) |
| Term | Meaning |
|---|---|
| f | femto (10–15 prefix of the SI) |
| f | Fraction absorbed (AUCev/AUCiv) |
| F | f given in percent |
| f1 | Difference factor (comparing dissolution profiles) |
| f2 | Similarity factor (comparing dissolution profiles) |
| FAIMS | Field Asymmetric Waveform Ion Mobility Spectrometry |
| FA | Formic acid |
| FAQ | Frequently Asked Question |
| FAERS | FDA Adverse Event Reporting System |
| FaSSIF | Fasted-State Simulated Intestinal Fluid |
| FAT | Factory Acceptance Test |
| FC(MP) | Fixed Combination (Medicinal Product) |
| FDA | (United States) Food and Drug Adminstration |
| FDASIA | Food and Drug Administration Safety and Innovation Act (US) |
| FDC | Fixed-Dose Combination (Product) |
| FDF | Finished Dosage Form |
| FDR | False Discovery Rate |
| FeSSIF | Fed-State Simulated Intestinal Fluid |
| FEV1 | Forced Expiratory Volume in one second |
| FFF | Field Flow Fractionation |
| FFT | Fast Fourier Transformation |
| FG | Focus group |
| FID | Flame Ionization Detector in GC |
| FIM | First-In-Man (also FIH – First in Human) |
| FIP | Fédération internationale pharmaceutique (International Pharmaceutical Federation) |
| FL(D) | Fluorescence (Detection) in LC |
| FM | Fast metabolizer (also EM) |
| FNR | False Negative Rate (β, probability of Type II Error) |
| FOB | Follow-on Biologic |
| FOCE | First Order Conditional Estimation method in PopPK |
| FOIA | Freedom of Information Act (US) |
| FPIA | Fluorescence Polarization Immunoassay |
| FPP | Finished Pharmaceutical Product |
| FPR | False Positive Rate (α, probability of Type I Error) |
| FSOT | Fused Silica Open Tubular (capillary column in GC) |
| FT | Freeze/thaw (BMV) |
| FTIR | Fourier Transform Infrared Spectroscopy |
| FTP | File Transfer Protocol |
| FUM | Follow-up Measures |
| FWER | Familywise (Type I) Error Rate |
| Term | Meaning |
|---|---|
| g | Standard acceleration due to gravity at the Earth’s surface (SI: 9.80665 m/s²) |
| GaBI | Generics and Biosimilars Initiative |
| GALP | Good AutomatedLaboratory Practice(s) |
| GBC | Global Bioanalysis Consortium |
| GBHI | Global Bioequivalence Harmonisation Initiative |
| GBMA | Generic and Biosimilar Medicines Association (Australia) |
| GC | Gas Chromatography |
| GCC | Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, the United Arab Emirates) |
| GCP | Good Clinical Practice(s) |
| GCP IWG | Good Clinical Practice Inspectors Working Group (of the EMA) |
| GDP | Good Distribution Practice(s) |
| GDPR | General Data Protection Regulation (EU) |
| GDUFA | Generic Drug User Fee Act (US) |
| GENEZIS | Serbian and Montenegrin Generic and Biosimilar Medicines Association |
| G×F | Group-by-Formulation (Interaction) |
| GFR | Glomerular filtration rate |
| GI(T) | Gastrointestinal (Tract) |
| GITT | Gastrointestinal Transit Time |
| GL | Guideline |
| G(L)C | Gas (-Liquid) Chomatography |
| GLM | Generalized Linear Model |
| GLP | Good Laboratory Practice(s) |
| GMP | Good Manufacturing Practice(s) |
| GM(R) | Geometric Mean (Ratio) |
| GMT | Greenwich Mean Time (UK) |
| GPhA | Generic Pharmaceutical Association (US; merged in 2000 from the GPIA and the NPA and in 2001 with the NAPM, since 2017 AAM) |
| GPIA | Generic Pharmaceutical Industry Association (US; merged in 2000 to the GPhA) |
| GPL | GNU General Public License |
| GPO | (Microsoft’s) Group Policy Object |
| GSD | Group-Sequential Design |
| GUI | Graphical User Interface |
| GVP | Good Pharmacovigilance Practice(s) |
| Term | Meaning |
|---|---|
| h | Hour (also hr; non-SI unit) |
| H0 | Null Hypothesis |
| Ha | Alternative Hypothesis (also H1) |
| HA |
|
| Hb | H(a)emoglobin (also Hgb) |
| HC | Health Canada |
| HCP | Healthcare Professional |
| HETP | Height Equivalent of Theoretical Plate (in Chromatography) |
| HH[:mm][:ss] | ISO 8601 local time format (i.e., without UTC offset Z), where the minutes and seconds are optional; all values are zero-padded (HH: 00–24, mm: 00–59, ss: 00–60, where 60 is only used for an added leap second) |
| HILIC | Hydrophilic Interaction Liquid Chromatography |
| HMA | Heads of Medicines Agencies (of the EEA) |
| HMPC | Committee on Herbal Medicinal Products (of the EMA) |
| hν | Light |
| HPAE | High Performance Anion Exchange Chromatography |
| HPFB | Health Products and Food Branch (of HC) |
| HPLC | High Performance Liquid Chromatography (in the old days High Pressure LC) |
| HPTLC | High Performance Thin Layer Chromatography |
| HQC | High QC (sample) |
| HR | Heart rate |
| HSA | Health Sciences Authority (competent authority of Singapore) |
| HTA | Health Technology Assessment |
| HTML | Hypertext Markup Language |
| HTML5 | Hypertext Markup Language 5 (latest revision 5.2 of 2017) |
| HTTP | Hypertext Transfer Protocol |
| HV | Human Volunteer |
| HVD |
|
| HVDP | Highly Variable Drug Product |
| Term | Meaning |
|---|---|
| IA |
|
| IB | Investigator’s Brochure |
| IBD | Incomplete Block Design |
| IBE | Individual Bioequivalence |
| IBS | International Biometric Society |
| IBW | Ideal Body Weight |
| IC |
|
| ICBM | Intercontinental Ballistic Missile |
| ICD |
|
| ICF | Informed Consent Form |
| ICH | International Council for Harmonisation (until 10/2015 International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use) |
| ICH E | Efficacy Guideline of the ICH, e.g., |
| ICH M | Multidisciplinary Guideline of the ICH, e.g., |
| ICMR | Indian Council of Medical Research |
| ICP/MS | Inductively Coupled Plasma Mass Spectrometry |
| ICSR | Individual Case Safety Report |
| IDE | Integrated Development Environment |
| IDMPWG | Identification of Medicinal Products Working Group (of the IPRP) |
| i.e. | id est (that is) |
| IE | Inconclusive Evidence |
| IEC | Independent Ethics Committee |
| IEEE | Institute of Electrical and Electronics Engineers |
| IEF | Isoelectric Focusing |
| IF | Impact Factor |
| IGBA | International Generic and Biosimilars Medicines Association |
| IGDRP | International Generic Drug Regulators Programme |
| IID | Independent Identically Distributed (Random Variables) |
| IIRC | If I (recall/remember) correctly |
| IM | Intramuscular (also im) |
| IMHO | In my (humble/honest) opinion |
| IMI | Innovative Medicines Initiative (EU and EFPIA) |
| IMP | Investigational Medicinal Product (EU term) |
| IND | Investigational New Drug (FDA term) |
| INN | International Nonproprietary Name |
| INVIMA | Instituto Nacional de Vigilancia de Medicamentos y Alimentos (National Institute of Drug and Food Monitoring, competent authority of Colombia) |
| IP |
|
| IPA | Indian Pharmaceutical Alliance |
| IPAC-RS | International Pharmaceutical Aerosol Consortium on Regulation & Science |
| IPD | Individual Patient Data |
| IPR | Intellectual Property Rights |
| IPRP | International Pharmaceutical Regulators Programme |
| IQ | Installation Qualification |
| IQR | Interquartile Range (QIII – QI) |
| IR |
|
| IRB | Institutional Review Board |
| IRCTN | International Standard Randomized Controlled Trial Number |
| IRLS | Iteratively Reweighted Least Squares |
| IS | Internal Standard |
| ISBN | International Standard Book Number |
| ISCB | International Society for Clinical Biostatistics |
| ISCV | Intra-subjects Coefficient of Variation (also CVW, CVintra) |
| ISF | Investigator Site File |
| ISNI | International Standard Name Identifier |
| ISO | International Standards Organization |
| ISPR | Incurred Subject Period Re-analysis |
| ISR | Incurred Sample Re-analysis (also … Reproducibility) |
| ISSN | International Standard Serial Number |
| ISTQB | International Software Testing Qualifications Board |
| ISV | Internal Standard Variation |
| ITT | Intent-to-Treat |
| IU | International unit |
| IUD | Intrauterine device |
| IUPAC | International Union of Pure and Applied Chemistry |
| IUPHAR | International Union of Basic and Clinical Pharmacology |
| IUT | Intersection-Union Test |
| IV | Intravenous (also iv) |
| IVIVC | In vitro in vivo correlation |
| IVIVR | In vitro in vivo relationship |
| IVPT | In vitro permeation test |
| IVRS | Interactive Voice Response System |
| IVRT | In vitro release test |
| IW | Impartial witness |
| IWWG | Information Sharing Working Group for Generics (of the IPRP; 2014 – 2020) |
| IWRS | Interactive Web Response System |
| Term | Meaning |
|---|---|
| JAPM | Jordanian Association of Pharmaceutical Manufacturers |
| JFDA | Jordan Food and Drug Administration |
| JGA | Japan Generic Medicines Association |
| Term | Meaning |
|---|---|
| k | Regulatory constant in ABEL (see also \(\theta_\text{s}\)) |
| k’ | Capacity factor in chromatography \((\textsf{t}_\textsf{R}-\textsf{t}_0)/\textsf{t}_0\) |
| \(\textsf{k}_0\) | Infusion rate constant (also \(\textsf{k}_\textsf{in}\)) |
| \(\textsf{k}_\textsf{a}\) | Absorption rate constant (also \(\textsf{k}_{01}\)) |
| KASA | Knowledge-aided Assessment & Structured Application |
| \(\textsf{k}_\textsf{el}\) | Elimination rate constant (also \(\textsf{k}_{10}\)) |
| Kel | Elimination rate constant in guidelines (actually \(\widehat{\lambda}_\text{z}\)) |
| \(\textsf{k}_\textsf{xy}\) | Between compartments rate constant (where \(\textsf{x},\,\textsf{y}\neq 0\)) |
| KFDA | Korea Food & Drug Administration |
| KISS | Keep it simple, stupid |
| \(\textsf{K}_\textsf{m}\) | Michaelis-Menten constant |
| KR | Kenward-Roger approximation of degrees of freedom |
| Term | Meaning |
|---|---|
| l | levo enantiomer, according to IUPAC (–) |
| L | Lower limit of the reference-scaled average BE acceptance range (ABEL) \(=e^{-0.76\,\cdot\, s_\text{wR}}\) |
| LA | Long Acting (MR product) |
| LADME | Liberation, Absorption, Distribution, Metabolism, Excretion |
| LALA | Locally applied, locally acting (product) |
| LAR | Legally acceptable representative |
| LaTeX | Software system for typesetting documents based on TeX |
| LBA | Ligand Binding Assay |
| LC | Liquid Chromatography |
| LDH | Lactate dehydrogenase |
| LEC | Local Ethics Committee |
| LIF | Laser-induced Fluorescence |
| LIMS | Laboratory Information Management System |
| LL | Log likelihood |
| LLE | Liquid-Liquid Extraction |
| LLOQ | Lower Limit of Quantification |
| LLT | Lowest Level Term (MedDRA) |
| LMEM | Linear Mixed-Effects Model |
| LMICs | Low and Middle Income Countries |
| LOC | Lines of Code |
| LOCF | Last Observation Carried Forward |
| LOD | Limit of Detection (also DL) |
| \(\text{log}_{e}\) | Natural logarithm (base e ≈ 2.71828…) |
| \(\text{log}_{10}\) | Decadic logarithm (base 10) |
| LoI | Letter of Intent |
| LoOI | List of Outstanding Issues (authored by the CxMP and addressed to the Applicant at ca. day 180) |
| LoQ | List of Questions (authored by the CxMP and addressed to the Applicant at ca. day 120) |
| LOQ | Limit of Quantification (common meaning LLOQ) |
| LoU | Letter of Undertaking |
| LQC | Low QC (sample) |
| LR |
|
| LS | Least Squares |
| LSM | Least Squares Mean (SAS-lingo, aka Adjusted Mean) |
| Term | Meaning |
|---|---|
| m | milli (10–3 prefix of the SI) |
| MA | Marketing Authorisation (in the EEA) |
| MAA | Marketing Authorisation Application (in the EEA) |
| MAD |
|
| MAH | Marketing Authorisation Holder (in the EEA) |
| MALDI | Matrix-assisted Laser Desorption/Ionization |
| MALS | Multi-angle Light Scattering |
| MANOVA | Multivariate Analysis of Variance |
| MaPP | Manual of Policies and Procedures (FDA/CDER) |
| MAR | Missing at random |
| MAT | Mean Absorption Time |
| MathJAX | JavaScript library to render LaTeX in HTML5 |
| MatLab | Matrix Laboratory (numeric computing environment) |
| MathML | Mathematical Markup Language (application of XML and implemented in HTML5) |
| MB | Management Board |
| MCAR | Missing completely at random |
| MCC | Medicines Control Council (since 2017 SAHPRA) |
| mcg | Microgram (non-SI replacement for µg to avoid confusion with mg; acceptable if handwritten) |
| MCHC | Mean corpuscular h(a)emoglobin concentration |
| MCMC | Markov Chain Monte Carlo |
| MCP | Multiple Comparison Procedure |
| MCV | Mean corpuscular volume |
| MD |
|
| MD5 | Message-digest 5 |
| MDC | Minimum Detectable Concentration |
| MDI | Metered Dose Inhaler |
| MDL |
|
| MDR |
|
| MDT |
|
| ME | Matrix Effect |
| MEB | Medicines Evaluation Board (The Netherlands) |
| MEC | Minimum Effective Concentration |
| MED | Minimum Effective Dose |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MEDLINE | Medical Literature Analysis and Retrieval System Online (US) |
| MEDSAFE | New Zealand Medicines and Medical Devices Safety Authority |
| MEM | Mixed Effects Model |
| MENA | Middle East and North Africa |
| MeOH | Methanol |
| MeSH | Medical Subject Headings |
| MF | Matrix Factor |
| MFDS | Ministry of Food and Drug Safety (competent authority of the Republic of Korea) |
| MfE | Medicines for Europe (until 2016 EGA) |
| MHLW | Ministry of Health, Labour and Welfare (Japan) |
| MHRA | Medicines and Healthcare Products Regulatory Agency (UK) |
| MIC | Minimum Inhibitory Concentration |
| min |
|
| MIR | Mean of individual subject ratios |
| MIR | Mean of individual subject ratios |
| ML | Machine learning |
| MLE | Maximum Likelihood Estimator |
| M-M | Michaelis-Menten kinetics |
| MNAR | Missing not at random |
| MoH | Ministry of Health |
| MoM | Method of Moments |
| MOOSE | Meta-analysis Of Observational Studies in Epidemiology |
| MOPI | Malaysian Organisation of Pharmaceutical Industries |
| MP | Mobile Phase |
| MPA | Medicinal Products Act |
| MPH | Metylphenidate |
| MQC | Medium QC (sample) |
| MR | |
| MRFG | Mutual Recognition Fascilitation Group (of the EEA; since 2005 CMDh) |
| MRM | Multiple Reaction Monitoring (MS) |
| MRP | Mutual Recognition Procedure (in the EEA) |
| MRT | Mean of Residence Times (sloppy: Mean Residence Time) |
| MS |
|
| M&S | Modeling and Simulation |
| MSD | Multivariate Statistical Distance |
| MSE | Mean Squared Error |
| MS-MS | Tandem Mass Spectrometry |
| MSWP | Modeling and Simulation Working Party (of the CHMP); merged 2022 with other working parties in the MWP |
| MTD | Maximum Tolerated Dose (aka RP2D) |
| MVR | Monitoring Visit Report |
| MVUE | Minimum Variance Unbiased Estimator |
| MWP | Methodology Working Party (of the CHMP) |
| NWG | Nanomedicines Working Group (of the IPRP) |
| m/z | Mass/charge ratio (MS) |
| Term | Meaning |
|---|---|
| n | nano (10–9 prefix of the SI) |
| n | Number of values |
| N | (Total) sample size (also n) |
| n1 | Sample size of the first stage of a TSD, sample size of the first group of a GSD |
| n2 | Sample size of the second stage of a TSD, sample size of the second group of a GSD |
| NA | Not applicable |
| NB | nota bene (note well) |
| NAD | Nordic cooperation on alcohol and drugs |
| NAFDAC | National Agency for Food and Drug Administration and Control (competent authority of Nigeria) |
| NAP | Nationally Authorised Product |
| NAPM | National Association of Pharmaceutical Manufacturers (US; merged in 2001 with the GPhA) |
| NAT | N-acetyltransferase |
| NBCD | Non-Biological Complex Drug |
| NBE | New Biologic Entity |
| NC | Not calculable |
| NCA |
|
| NCE | New Chemical Entity (FDA term) |
| NCS | Not clinically significant |
| NDA |
|
| NDDS | Novel Drug Delivery System |
| NE | Not estimable |
| NfG | Note for Guidance (of the EMEA) |
| NHA | National Health Authority |
| NHMRC | National Health and Medical Research Council (competent authority of Australia) |
| NIH | National Institutes of Health (US) |
| NIHS | National Institute for Health Sciences (Japan) |
| NIMP | Non Investigational Medicinal Product (EU GMP term) |
| NIS | Non-interventional Study |
| NIST | National Institute of Standards and Technology (US) |
| NLM | US National Library of Medicine |
| NLME | Pharsight’s PopPK software |
| NLMEM | Nonlinear Mixed-Effects Model |
| NLT | Not less than |
| NLYW | Nice looking young woman (© ElMaestro) |
| NMA | National Medical Association |
| NME | New Molecular Entity (FDA term) |
| NMPA, CDE | National Medical Products Administration, Center for Drug Evaluation (formerly CFDA) |
| NMR | Nuclear Magnetic Resonance |
| NOAC | Novel Oral Anticoagulant |
| NOAEL | No Observed Adverse Effect Level |
| NOC | No Objection Certificate (CDSCO) |
| NOL | No Objection Letter |
| NOMESKO | Nordic Medico-Statistical Committee |
| NONMEM | ICON Development Solutions’ PopPK software |
| NPA | National Pharmaceutical Alliance (US; merged in 2000 to the GPhA) |
| NPD | Nitrogen-Phosphorus Detector in GC |
| NPRA | National Pharmaceutical Regulatory Agency (competent authority of Malaysia) |
| NPV | Negative Predictive Value |
| NQ | Not quantifiable |
| NR |
|
| NRC | National Research Council (US) |
| n.s. | Not significant |
| NSAID | Nonsteroidal anti-inflammatory drug |
| NSB | Non specific binding |
| Nt | Number of theoretical plates (chromatography) |
| NtA | Notice to Applicants (EMA) |
| NTA | Nanoparticle Tracking Analysis |
| NTI(D) | Narrow Therapeutic Index (Drug) |
| NTR | Narrow Therapeutic Range |
| Term | Meaning |
|---|---|
| OA | Open Access |
| OAD | Once a day |
| OD | Overdose |
| ODT | Orodispersible Tablet |
| OECD | Organisation for Economic Co-operation and Development |
| OF | Objective Function |
| OGD | Office of Generic Drugs (of the FDA’s CDER) |
| OGDP | Office of Generic Drug Policy (of the FDA’s CDER) |
| OIP | Orally Inhaled Product |
| OL | Outlier |
| OLS | Ordinary Least Squares |
| ONDQA | Office of New Drug Quality Assessment (of the FDA’s CDER) |
| OP | Original post(er) |
| OPD | Once per day |
| OPPI | Organisation of Pharmaceutical Producers of India |
| OQ | Operational Qualification |
| ORA | Office of Regulatory Affairs (of the FDA) |
| ORCID | Open Researcher and Contributor ID |
| OROS | Osmotic Release Oral System (MR) |
| OS |
|
| OT | Off Topic |
| OTC | Over-the-counter |
| Term | Meaning |
|---|---|
| p |
|
| \(p(\textsf{x})\) | Probability of \(\textsf{x}\) |
| PA | Precision and Accuracy (BMV) |
| PAD |
|
| PAGANZ | Population Approach Group in Australia and New Zealand |
| PAGE |
|
| PAH | Polycyclic aromatic hydrocarbon |
| PAHO | Pan American Health Organization |
| PAMPA | Parallel Artificial Membrane Permeability Assay |
| PAR | Public Assessment Report |
| PAS | Prior Approval Supplement (FDA term) |
| PAT | Process Analytical Technology |
| \(\textsf{pAUC}_{\textsf{t}_{1}-\textsf{t}_{2}}\) | Partial AUC (within \(\left\{\textsf{t}_1,\textsf{t}_2\right\}\)) |
| PB | Protein binding |
| PBE | Population Bioequivalence |
| PBPK | Physiologically Based Pharmacokinetics |
| p.c. | post cibum (after food) |
| PCA |
|
| PD | Pharmacodynamics |
| PDCO | Paediatric Committee (of the EMA) |
| PDE5 | Phosphodiesterase type 5 |
| |
| PDR | Physicians’ Desk Reference |
| PDUFA | Prescription Drug User Fee Act (US) |
| PE |
|
| PEG | Polyethylene glycol |
| PEI | Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biological Medicinal Products, Germany) |
| PFA | Principal Factor Analysis |
| PFTBA | Perfluorotributylamine |
| PGP | P-glycoprotein |
| pH | Pons hydrogenii (power of hydrogen): negative decadic logarithm of the H+-activity \(=-\log_{10}(a_{\text{H}^+})\) |
| Ph.Br. | Pharmacopoeia Britannica (British Pharmacopoeia) |
| Ph.Eur. | Pharmacopoeia Europaea (European Pharmacopoeia) |
| Ph.Int. | Pharmacopoeia Internationalis (International Pharmacopoeia) |
| PhRMA | Pharmaceutical Research and Manufacturers of America |
| PHX | Certara’s “Phoenix” software |
| PI |
|
| PIC/S | Pharmaceutical Inspection Co-operation Scheme |
| PIL | Patient Information Leaflet (EU) |
| PIP | Paediatric Investigation Plan |
| PIS | Patient Information Sheet |
| PK | Pharmacokinetics |
| pKa | Acid dissociation constant: negative decadic logarithm of the acid-ionization constant \(K_a\) \(=-\log_{10}(K_a)\) |
| PKPD | PK-PD model |
| PKWP | Pharmacokinetics Working Party (of the EMA’s CHMP); merged 2022 with other working parties in the MWP |
| PL | Package Leaflet |
| PM |
|
| PMA |
|
| PMDA | Pharmaceuticals and Medical Devices Agency (competent authority of Japan) |
| PMI | Prescription Medication Information (FDA term) |
| PMID | PubMed identifier |
| PO | per os (orally; also po) |
| POM | Prescription-only Medicine |
| PopPK | Population Pharmacokinetics |
| PopPKPD | Population Pharmacokinetics-Pharmacodynamics |
| POT-25 | Peak Occupancy Time 25 (time interval where \(\textsf{C}\geq \textsf{75% C}_\textsf{max}\); aka t75%) |
| POT-50 | Peak Occupancy Time 50 (time interval where \(\textsf{C}\geq \textsf{50% C}_\textsf{max}\); aka HVD) |
| PowerTOST | Power and sample size based on the TOST-procedure for BE studies (package for |
| p.p. | post prandium (after a meal) |
| PP | Per Protocol |
| PPI | Proton Pump Inhibitor |
| PPV | Positive Predictive Value |
| PPT | Protein Precipitation |
| PQ | Performance Qualification |
| PQM+ | Promoting the Quality of Medicines Plus (collaboration of the USP and USAID) |
| PQP | Prequalification of Medicines Programme (WHO) |
| PQT | Prequalification Team (WHO) |
| PQRI | Product Quality Research Institute |
| PQTm | WHO Prequalification Team – Medicines |
| PR | Pulse rate |
| PRAC | Pharmacovigilance Risk Assessment Committee (of the EMA) |
| PRIME | Priority Medicine |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PRNG | Pseudorandom number generator |
| PSAP | Program Safety Analysis Plan |
| PSD | Particle Size Distribution |
| PSG | Product-Specific Guidance |
| PSRtPH | Potential Serious Risk to Public Health (EEA term) |
| PSUR | Periodic Safety Update Report (in the EEA) |
| pt | Point |
| PT | Preferred Term (MedDRA) |
| PtC | Points to Consider (of the EMEA/EMA) |
| %PTF | Percent Peak-Trough Fluctuation \(=100(\textsf{C}_\textsf{max,ss}-\textsf{C}_\textsf{min,ss})/\textsf{C}_\textsf{av,ss}\), where \(\textsf{C}_\textsf{av,ss}=\textsf{AUC}_{0-\textsf{τ}}/\textsf{τ}\) |
| PTL | Product Team Leader (EMA) |
| PubMed | Public MEDLINE |
| PV | Pharmacovigilance |
| PVAR | Preliminary Variation Assessment Report |
| PVT | Performance Verification Testing |
| ℞ | Prescription (also Rx) |
| Term | Meaning |
|---|---|
| Q | Quarter |
| QA |
|
| Q&A | Questions and Answers |
| QAU | Quality Assurance Unit |
| QbD | Quality by Design |
| QC | Quality Control |
| Q.E.D. | quod erat demonstrandum (what was to be demonstrated, end of proof; also ∎ or □) |
| QH | Hepatic blood flow |
| QI, QIII | First, third quartile (25%, 75% percentile) |
| QM(S) | Quality Management (System) |
| QoL | Quality of life |
| QP | Qualified Person (in the EU) |
| QPPV | Qualified Person for Pharmacovigilance (in the EU) |
| Q-Q | Quantile-Quantile |
| QR | Renal blood flow |
| QT | Interval defined by start of the Q wave to the end of the T wave |
| QTcB | QT corrected for HR by Bazett’s formula |
| QTcT | QT corrected for HR by Fridericia’s formula |
| QTPP | Quality Target Product Profile |
| QWG | Quality Working Group (of the IPRP) |
| QWP | Quality Working Party (of the EMA’s CHMP) |
| Term | Meaning |
|---|---|
| R |
|
| \(R\) | Coefficient of correlation |
| A language and environment for statistical computing and graphics (OS implementation of S, licensed under the GPL) | |
| (R) | rectus (right) stereocenter according to the CIP |
| \(R^2\) | Coefficient of determination |
| \(R_{\text{adj}}^2\) | \(R^2\) adjusted for sample size (and number of estimated parameters) |
| RA | Regulatory Authority |
| RBC | Red blood cells |
| RCA | Root Cause Analysis |
| RCF | Relative Centrifugal Force (more common: × g) |
| RCT | Randomized controlled (or clinical) trial |
| R&D | Research and Development |
| RDE | Remote Data Entry |
| RD/OMP | Rare Disease & Orphan Medicinal Product |
| %RE | Percent Relative Error, bias \(=100(\widehat{\textsf{x}}-\textsf{x})/\textsf{x}\), where \(\widehat{\textsf{x}}\) is the estimated and \(\textsf{x}\) the true value |
| REML(E) | Restricted Maximum Likelihood (Estimator) |
| REMS | Risk Evaluation Mitigation Strategies (FDA term) |
| RFC | Request for Comments |
| R·HCl | Hydrochloride of base R |
| RHI | Regional Harmonisation Initiative |
| RI | Refractive Index |
| RIA | Radioimmunoassay |
| RLD | Reference Listed Drug (FDA term) |
| Rmax | Maximum Excretion Rate |
| RMP |
|
| RMS | Reference Member State (in European MRP) |
| ROA | Route of Administration |
| ROC | Receiver Operating Characteristic |
| RP |
|
| RP2D | Recommended Phase II Dose (aka MTD) |
| rpm | Rotations per minute (only if the geometry is defined – like in dissolution apparatuses; uninformative in centrifugation, see RCF) |
| RSABE | Reference-Scaled Average Bioequivalence |
| RSD | Relative Standard Deviation (\(s_x/\overline{x}\), aka CV) |
| RSS | Rich Site Summary |
| RT |
|
| RTF | Rich Text Format |
| RTFM | Read The Fucking Manual |
| RTR | Refuse-to-Receive (in an ANDA) |
| RTRT | Real-time Release Testing |
| RWE | Real-world evidence |
| RWD | Real-world data |
| Term | Meaning |
|---|---|
| \(s\) | Sample standard deviation (also SD) |
| S | Programming language for statistics |
| (S) | sinister (left) stereocenter according to the CIP |
| \(s^2\) | Sample variance |
| SAAM | Scientists Advancing Affordable Medicines (US) |
| SAE | Serious Adverse Event |
| SABE | Scaled Average Bioequivalence |
| SAE | Serious Adverse Event |
| SAEM | Stochastic Approximation Expectation Maximization |
| SAP | Statistical Analysis Plan |
| SAHPRA | South African Health Products Regulatory Agency (until 2017 MCC) |
| SAR |
|
| SAS | Statistical Analysis System |
| SAT | Site Acceptance Test |
| SAWP | Scientific Advice Working Party (of the EMA) |
| SBC | Schwarz’ Bayesian Criterion (aka BIC) |
| SBP | Systolic blood pressure |
| SC | Subcutaneous (also sc) |
| SCNR | Sorry, could not resist! |
| SCOT | Support-Coated Open Tubular (capillary column in GC) |
| SD |
|
| SDS | Sodium Dodecyl Sulfate (also SLS = Sodium Lauryl Sulfate) |
| SDTM | Study Data Tabulation Model (of the CDISC) |
| SE | Standard Error (also SEM, Standard Error of the Mean) |
| SEB | Subsequent Entry Biologic |
| SEC | Size Exclusion Chromatography |
| SEDDS | Self-Emulsifying Drug Delivery System |
| SEE | Study exit examination |
| SEND | Standard for Exchange of Nonclinical Data (of the CDISC) |
| S×F | Subject-by-Formulation (Interaction) |
| SFC | Supercritical Fluid Chromatography |
| SFDA |
|
| SFU | Safety follow-up |
| SGF | Simulated Gastric Fluid |
| SGML | Standard Generalized Markup Language |
| SGOT | Serum glutamic oxaloacetic transaminase |
| SGPT | Serum glutamic pyruvic transaminase |
| SHA | Secure Hash Algorithm |
| SHAM | Shape, Height, Area, Moments (aka NCA) |
| SI | Système international d’unités (International System of Units) |
| SIF | Simulated Intestinal Fluid |
| SIL(IS) | Stable isotope labeled (internal standard) |
| SIM | Single Ion Monitoring (MS) |
| Sim’s | (Number of) simulations |
| SIR | Single Ion Recording (MS) |
| SL | Sublingual |
| SLS | Sodium lauryl sulfate |
| SM |
|
| SMILES | Simplified Molecular-Input Line-Entry System |
| SMO | Site Management Organisation |
| SmPC | Summary of Product Characteristics (EEA term) |
| S/N | Signal/noise ratio |
| SOC | System Organ Class (MedDRA term) |
| SODF | Solid Oral Dosage Form |
| SOP | Standard Operating Procedure |
| SPE | Solid Phase Extraction |
| S-PLUS | Commercial implementation of S |
| SPSS | Statistical Product and Service Solutions (formerly Statistical Package for the Social Sciences) |
| SQL | Structured Query Language |
| SR | Sustained Release MR product (also CR, LA, XR) |
| SRM | Selected Reaction Monitoring (MS) |
| SRS | Spontaneous Reporting System |
| ss | Steady state |
| SS |
|
| SSR | Sample Size Reassessment (or Re-estimation) |
| SSRI | Serotonin-specific re-uptake inhibitor |
| SST | System Suitability Test |
| STFW | Search The Fucking Web |
| SUPAC | Scale-Up and Post-Approval Changes (FDA term) |
| SUSAR | Suspected Unexpected Serious Adverse Reaction (EEA term) |
| swissmedic | Swiss Agency for Therapeutic Products (competent authority of Switzerland) |
| SWP | Safety Working Party (of the EMA’s CHMP) |
| \(s_{\text{wR}}\) | Within-subjects standard deviation of the Reference product estimated in a replicate design |
| \(s_{\text{wT}}\) | Within-subjects standard deviation of the Test product estimated in a fully replicated design |
| Term | Meaning |
|---|---|
| T | Test (product, treatment) in comparative BA |
| t0 | Elution time of void (chromatography) |
| \(\textsf{t}^\ast\) | Length of infusion |
| \(\textsf{t}_\boldsymbol{½}\) | Half life time \(=\frac{\log_e(2)}{\widehat{\lambda}_\text{z}}\) |
| \(\textsf{t}_\textsf{75%}\) | Plateau Time (time interval where \(\textsf{C}\geq \textsf{75% C}_\textsf{max}\); aka POT-25) |
| TAD | Time after dose (common notation in PopPK) |
| \(\textsf{t}_\textsf{apical}\) | Average of times within POT-25 |
| TAW | Time Allowance Window |
| TB | Tuberculosis |
| t.b.d. | To be determined |
| TBIL | Total bilirubin |
| TBM | To-be-marketed (formulation) |
| TCA |
|
| TCD | Thermal Conductivity Detector in GC |
| TCOL | Total cholesterol |
| TDDS | Transdermal Delivery System |
| TDM | Therapeutic Drug Monitoring |
| TDS | Transdermal System |
| TE | Therapeutic Equivalence |
| TEAE | Treatment-emergent adverse event |
| TeX | Typesetting program |
| TGA | Therapeutic Goods Administration (Australia) |
| TGD | Therapeutic Products Directorate (of HC’s HPFB) |
| TGPA | Taiwan Generic Pharmaceutical Association |
| TFDA | Taiwan Food and Drug Administration |
| TIC | Total Ion Current (MS) |
| TID | ter in die (thrice a day) |
| TIE | Type I Error |
| TİTCK | Türkiye İlaç ve Tıbbi Cihaz Kurumu (Turkish Medicines and Medical Devices Agency) |
| TK | Toxicokinetics |
| \(\textsf{t}_\textsf{lag}\) | Lagtime |
| \(\textsf{t}_\textsf{last}\) | Time point of the last measured concentration of the profile (also \(\textsf{t}_\textsf{z}\)) |
| \(\textsf{t}_\textsf{last (Common)}\) | Last time point where a subject’s concentrations after all treatments are quantifiable |
| TLC | Thin Layer Chromatography |
| TLP | Top level post |
| \(\textsf{t}_\textsf{max},\,\textsf{t}_\textsf{max,ss}\) | Time point of maximum concentration (single dose, steady state); observed in NCA, estimated by PK modeling |
| TMF | Trial Master File |
| \(\textsf{t}_\textsf{min,ss}\) | Time point of minimum concentration in steady state; observed in NCA, estimated by PK modeling |
| TNR | True Negative Rate (Specificity) |
| TPA | Therapeutic Products Act |
| TOF | Time-of-Flight (MS) |
| TOFU |
|
| TOST | Two One-Sided Tests |
| TPP | Target Product Profile |
| TPR | True Positive Rate (Sensitivity) |
| tR | Retention time (aka RT) |
| T/R | Test/Reference ratio (also GMR) |
| TRIG | Triglycerides |
| Troll |
|
| TRIG | Triglycerides |
| TSD | (Adaptive) Two-Stage Design |
| TSH | Thyroid-stimulating hormone |
| TSV | Tab-Separated Values |
| TTT | Two times \(\textsf{t}_\textsf{max}\) |
| TTTP | Two-treatment, two-period (crossover) |
| Term | Meaning |
|---|---|
| U | Upper limit of the reference-scaled average BE acceptance range (ABEL) \(=e^{+0.76\,\cdot\, s_{\text{wR}}}\) |
| UAC | Uric acid |
| uc | Upper cap of expansion in ABEL (EMA and most other agencies at CVwR = 50%, HC at ≈ 57.382%) |
| ug | Microgram (non-SI replacement for µg; acceptable on 7-bit text systems) |
| UHPLC | Ultrahigh-Pressure Liquid Chromatography |
| UIR | Unit Impulse Response |
| UL | Upper total sample size limit in TSDs |
| ULOQ | Upper Limit of Quantification |
| UMR | Urinary metabolic ratio |
| URI | Uniform Resource Indicator |
| URL | Uniform Resource Locator |
| URS | User Requirement Specifications |
| USAID | United States Agency for International Development (eradicated in 2025 Trumpistan) |
| USAN | United States Adopted Name |
| USP | United States Pharmacopeia |
| UTC | Coordinated Universal Time (in the UK GMT) |
| UTF | Unicode Transformation Format |
| UV | Ultraviolet |
| Term | Meaning |
|---|---|
| Varea | Apparent Volume of Distribution (aka Vβ) |
| VAS | Visual analog scale |
| VBA | (Microsoft’s) Visual Basic for Applications |
| Vd | Volume of Distribution of the central compartment (also Vc, V1) |
| VIF | Variance Inflation Factor |
| VIS | Visible (light) |
| Vm | Maximum elimination rate (Michaelis-Menten kinetics) |
| VPC | Visual Predictive Check |
| vs | versus (against, compared to) |
| Vss | Apparent Volume of Distribution in steady state |
| Term | Meaning |
|---|---|
| w | Weight |
| w0.5 | Peak’s width at ½ of its height |
| WBC | White blood cells |
| WCOT | Wall-Coated Open Tubular (capillary column in GC) |
| WHO | World Health Organization |
| WHO-UMC | WHO-Uppsala Monitoring Centre |
| WHOART | WHO Adverse Event Terminology |
| WIPO | World Intellectual Property Organization |
| WMA | World Medical Association |
| WN | Wagner-Nelson (method of estimating absorption) |
| WNL | Certara’s “WinNonlin” software |
| WO | Wash-out (phase) in crossover designs |
| WSS | Weighted Sum of Squares |
| WTO | World Trade Organization |
| Term | Meaning |
|---|---|
| x | Independent variable |
| \(\overline{\textsf{x}}\) | (Arithmetic) sample mean |
| \(\widetilde{\textsf{x}}\) | Sample median |
| \(\overline{\textsf{x}}_\textsf{geom}\) | Geometric sample mean (also GM) |
| \(\overline{\textsf{x}}_\textsf{harm}\) | Harmonic sample mean |
| (X)HTML | (Extensible) Hypertext Markup Language |
| XML | Extensible Markup Language |
| Xover, XO | Crossover (design) |
| XR | Extended Release MR product (aka ER; also CR, LA, SR) |
| XRD | X-Ray Diffraction |
| Term | Meaning |
|---|---|
| y | |
| YMHS | Young Male Healthy Subject |
| YYYY[-MM][-DD] | ISO 8601 date format, where the months and days are optional; all values are zero-padded (MM: 01–12, DD: 01–31) |
| Term | Meaning |
|---|---|
| z | Index denoting the last value of a profile (examples: \(\widehat{\lambda}_\textsf{z}\), \(\textsf{t}_\textsf{z}\)) |
| Z | Offset of the local time to UTC given as ±HH:mm or ±HHmm, where HH and mm have to be given with a leading zero if ≤ 9
|
| ZL | Zentrallaboratorium Deutscher Apotheker (Central Laboratory of German Pharmacists) |
| Term | Meaning |
|---|---|
| \(1-\beta\) | Power (rarely \(\pi\)) |
| 2×2×2 | 2-treatment, 2-sequence, 2-period crossover design (also 2×2, TR|RT, 2,2,2) |
| 2×2×3 | 2-treatment, 2-sequence, 3-period full replicate designs (TRT|RTR, TRR|RTT) |
| 2×3×3 | 2-treatment, 3-sequence, 3-period partial replicate designs (TRR|RTR|RRT, TRR|RTR) |
| 2×2×4 | 2-treatment, 2-sequence, 4-period full replicate designs (TRTR|RTRT, TRRT|RTTR, TTRR|RRTT) |
| 2×4×2 | 2-treatment, 4-sequence, 2-period (Balaam’s) design (TR|RT|TT|RR) |
| 3×3×3 | 3-treatment, 3-sequence, 3-period (Latin Square) design (also 3×3, ABC|BCA|CAB) |
| 3×6×3 | 3-treatment, 6-sequence, 3-period (Williams’) design (ABC|ACB|BAC|BCA|CAB|CBA) |
| 3R | Reduction, Replacement, and Refinement |
| 4GL | Fourth-generation programming language |
| 666 | Ἀριθμὸς τοῦ θηρίου |
| Term | Meaning |
|---|---|
| \(\alpha\) |
|
| \(\alpha_\text{adj}\) | Adjusted \(\alpha\) (multiplicity correction) |
| \(\alpha_\text{emp}\) | Empiric \(\alpha\) (obtained in simulations) |
| \(\beta\) |
|
| \(\beta_\text{emp}\) | Empiric \(\beta\) (obtained in simulations) |
| \(\gamma\) | Mass concentration (IUPAC) |
| \(\it{\Delta}\) | (Clinically relevant) difference in comparative BA |
| \(\delta\) | Margin of clinical relevance in Non-Inferiority/Superiority and Non-Superiority |
| \(\delta_\text{a},\,\delta_\text{s}\) | Polli and McLean metrics |
| \(\epsilon\) | Residual error |
| \(\eta\) | Random effect in PopPK |
| \(\theta\) | Subject’s parameter value in PopPK |
| \(\theta_0\) | Expected ratio |
| \(\theta_{1,2}\) | Lower (1) and upper (2) limit of the acceptance range |
| \(\theta_\text{s}\) | Regulatory switching condition in RSABE (see also k) |
| \(\widehat{\lambda}_\text{z}\) | Apparent (estimated) terminal rate constant (in guidelines sloppy Kel) |
| μ | micro (10–6 prefix of the SI) |
| \(\mu\) | Population mean |
| \(\nu\) | Degrees of freedom (also df) |
| \(\xi\) | Rescigno’s BE index |
| \(\pi\) | Power \(=1-\beta\) |
| \(\pi_\text{emp}\) | Empiric power (obtained in simulations \(=1-\beta_\text{emp}\)) |
| \(\Pi\) | Product |
| \(\rho\) |
|
| \(\rho,\,\rho_\text{m}\) | Polli and McLean metrics |
| \(\sigma\) | Population standard deviation |
| \(\sigma_0\) | Regulatory standardized variation |
| \(\sigma^2\) | Population variance |
| \(\Sigma\) | Sum |
| \(\textsf{τ}\) | Dosing interval |
| \(\psi\) | Chinchilli metric |
| Term | Meaning |
|---|---|
| \(\in\) | Element of |
| \(\notin\) | Not an element of |
| \(\subset\) | (Proper) subset |
| \(\subseteq\) | Subset (border elements included) |
| \(\nsubseteq\) | Not a subset |
| \(\cap\) | Intersection |
| \(\cup\) | Union |
| \(\propto\) | Proportional to |
| \(\int\) | Integral |
| \(\sqrt{}\) | Square root (aka radical sign, radix) |
| \(\infty\) | Infinity |
| \(\wedge\) | And |
| \(\vee\) | Or |
| \(\neg\) | Not |
| \(\equiv\) | Identical |
| \(\sim\) | Similar |
| \(\approx\) | Approximately equal |
| \(\neq\) | Not equal |
| \(\leq\) | Less or equal than |
| \(\geq\) | Greater or equal than |
| \(\ll\) | Much less than |
| \(\gg\) | Much greater than |
| \(\mathbb{N}\) | Integer (number) |
| \(\mathbb{R}\) | Real (number) |
| \(\mathbb{R}^{+}\) | Positive real number |
| \(\ldots\) | Ellipsis |
| \(\small{\blacksquare}, \small{\square}\) | quod erat demonstrandum (what was to be demonstrated), end of proof |
The Bioequivalence / Bioavailability Forum is hosted by
Ing. Helmut Schütz
Established 2004-07-30 | last update 2025-01-22 | document date 2013-12-12 | modified 2025-10-29